Stock Details
JNJ is Johnson & Johnson's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 175.47$. Average daily volumn in 3 months 6.58M. Market cap 439.83B



Stock symbol : JNJ. Exchange : NYSE. Currency : USD
Lastest price : 168.23$. Total volume : 5.88M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Johnson & Johnson (JNJ)
Last Price
168.23$
Change
-0.66
Volume
5.88M

Previous Close168.89
Open168.54
Day Range167.77-168.87
Bid0.00 x 900
Ask0.00 x 800
Volume5.88M
Average Volume6.58M
Market Cap439.83B
Beta0.57
52 Week Range155.72-186.69
Trailing P/E25.00
Foward P/E15.42
Dividend (Yield %)2.69%
Ex-Dividend Date2023-02-17



Financial Details


According to Johnson & Johnson's financial reports the company's revenue in 2023 were 94.94B an increase( +1.08%) over the years 2022 revenue that were of 93.78B. In 2023 the company's total earnings were 17.94B while total earnings in 2022 were 20.88B(-15%).


Loading ...



Organization

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC... allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Market Cap:
439.83B
Revenue:
94.94B


News about "Johnson & Johnson"

Johnson & Johnson fourth-quarter earnings down 25%

Source from : Fox Business - 4 days ago

Johnson & Johnson reported a 25% drop in earnings and declining sales for the fourth quarter as demand dropped for its Covid-19 vaccine, while providing a cautious forecast for sales growth as the ...See details»


Johnson & Johnson stock outperforms competitors on strong trading day

Source from : MarketWatch - 3 days ago

Shares of Johnson & Johnson JNJ inched 0.71% higher to $169.51 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...See details»


Johnson & Johnson (JNJ) Q4 2022 Earnings Call Transcript

Source from : Seeking Alpha - 4 days ago

Good morning and welcome to Johnson & Johnsonโ€™s Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.See details»


Johnson & Johnson stock remains steady Tuesday, still outperforms market

Source from : MarketWatch - 4 days ago

Shares of Johnson & Johnson JNJ were unchanged Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.31% to ...See details»


Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Source from : Yahoo Finance - 3 days ago

Johnson & Johnson in Focus Johnson & Johnson (JNJ) is headquartered in New Brunswick, and is in the Medical sector. The stock has seen a price change of -4.72% since the start of the year.See details»


Johnson & Johnson Reports Q4 and Full-Year 2022 Results

Source from : Yahoo Finance - 5 days ago

As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value." OVERALL FINANCIAL RESULTS Q4 Full Year ...See details»


Johnson & Johnson (JNJ) Stock Moves -1.51%: What You Should Know

Source from : Yahoo - 10 days ago

In the latest trading session, Johnson & Johnson (JNJ) closed at $169.76, marking a -1.51% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.56%. Meanwhile ...See details»


Johnson & Johnson's 4Q earnings beat and rosy 2023 outlook fails to distract from slowing sales growth and inflationary pressures

Source from : Proactiveinvestors - 4 days ago

Johnson & Johnson (NYSE:JNJ)โ€™s rosy 2023 earnings forecast failed to take the sting off of moderated sales growth and inflationary pressures during the fourth quarter of 2022. For the three-month ...See details»


Johnson & Johnson (JNJ) Q4 Earnings Top Estimates

Source from : Nasdaq - 5 days ago

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.13 per share a year ago.See details»


Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates

Source from : Business Insider - 5 days ago

(RTTNews) - Healthcare company Johnson & Johnson (JNJ) on Tuesday reported that profit for fourth quarter declined 25.9 percent from last year, reflecting a sales decline and higher provisions for ...See details»


Johnson & Johnson Files for IPO of Consumer Health Division Kenvue

Source from : TheStreet.com - 23 days ago

Johnson & Johnson (JNJ) - Get Free Report shares edged lower Thursday after the group unveiled plans to list its consumer healthcare division as a stand-alone company with around $15 billion in ...See details»


Johnson & Johnson Q4 Profit Decreases, but beats estimates

Source from : Business Insider - 5 days ago

(RTTNews) - Johnson & Johnson (JNJ) reported earnings for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's earnings totaled $3.52 billion ...See details»


Johnson & Johnson ends trial for HIV vaccine after data show it is ineffective

Source from : Washington Examiner - 10 days ago

Johnson & Johnson said Wednesday that it has ended a late-stage trial for its experimental HIV vaccine after data showed the shot was ineffective at preventing infections. The experimental HIV ...See details»


Johnson & Johnson Is A Better Dividend Stock Than Roche, Despite A 20% Lower Yield

Source from : Seeking Alpha - 17 days ago

Shares of Johnson & Johnson (NYSE:JNJ), the world-renowned healthcare, medical device, and consumer health conglomerate, are rightfully a key component of many dividend growth portfolios.See details»